Nucana
NCNA----
Nucana (NCNA)
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies i...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
- 52wk Low
- --
- Float Mkt Cap
- --
- Market Cap
- --
- P/ETTM
- --
- P/EDynamic
- --
- P/EStatic
- --
- EPSTTM
- --
- EPSDynamic
- --
- EPSStatic
- --
- BVPS
- --
- P/B
- --
- Circulating Supply
- --
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- --
- Min lot size
- --
- Currency
- --
Nucana Analyst Rating
View moreForecast & Rating
Mar 31, 2025Price forecast
$20800.002110932.17%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT ·
NuCana says EPO grants European composition-of-matter patent for NUC-7738
- PUBT ·
NuCana publishes corporate oncology presentation on ProTide platform
- benzinga_article ·
12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga_article ·
12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga_article ·
12 Health Care Stocks Moving In Friday's After-Market Session
